Clinical Care Options Oncology - Myelodysplastic Syndromes: Integrating Novel Agents Into Current Treatment Algorithms

Module

Understanding Myelodysplastic Syndromes: Diagnosis, Classification, and Treatment

Faculty:

Naomi Galili, PhD
Azra Raza, MD

CREDIT INFORMATION

Release Date: November 03, 2009

Expiration Date: November 02, 2010

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Status: Please log in to view status

Naomi Galili, PhD, and Azra Raza, MD, discuss recent advances in the diagnosis, classification, and treatment of MDS.

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the classification criteria for MDS
Review standard treatment approaches for patients with MDS
Summarize experimental treatment approaches for patients with MDS
Cite cytogenetic abnormalities associated with MDS

Abstract

Click here to view abstract

Interactive Tool

Treatment Recommendations for Patients With Myelodysplastic Syndrome

This interactive decision support tool is designed to determine optimal treatment recommendations for a patient with myelodysplastic syndrome based on treatment guidelines and expert faculty input.

Format: HTML

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

CCO Treatment Updates

Myelodysplastic Syndromes: Integrating Novel Agents Into Current Treatment Algorithms